ATX-101 for Post-surgical Pain Following Total Knee Arthroplasty

  • End date
    Jun 30, 2023
  • participants needed
  • sponsor
    Allay Therapeutics, Inc.
Updated on 30 June 2022


This is a Phase 2B randomized, double blind, placebo and active controlled, multi-center clinical trial to evaluate the safety and efficacy of ATX-101 in participants following total knee arthroplasty.

Condition Acute Postoperative Pain
Treatment Placebo, ATX-101, bupivacaine hydrochloride without epinephrine
Clinical Study IdentifierNCT05260008
SponsorAllay Therapeutics, Inc.
Last Modified on30 June 2022


Yes No Not Sure

Inclusion Criteria

Primary indication of total knee arthroplasty is knee pain due to osteoarthritis or post-traumatic arthritis
Scheduled to undergo primary unilateral total knee arthroplasty with a cemented prosthesis, without use of a surgical drain, and under bupivacaine spinal anesthesia (dextrose is permitted)
American Society of Anesthesiology (ASA) Physical Classification System of class 1, 2 or 3

Exclusion Criteria

Has a planned concurrent surgical procedure
Has had any previous arthroplasty, unicompartmental knee arthroplasty or total knee arthroplasty in the study knee or previous arthroplasty, unicompartmental knee arthroplasty, or total knee arthroplasty in the contralateral knee within 6 months prior to screening
Has been administered any type of intra-articular injection within 3 months of surgery in the trial knee
Immunocompromised or has a known history of Hepatitis B, human immunodeficiency virus (HIV), or Hepatitis C
Routinely take opioid analgesics and are expected to require opioid analgesics in the postsurgical period that is not strictly related to the trial
Unable to abstain from opioid use for knee pain within 14 days of surgery
Has been administered systemic steroids within 14 days prior to surgery
Has been administered any local anesthetic within 5 days prior to the scheduled surgery
Screening electrocardiogram (ECG) with significant abnormalities associated with significant heart disease
Has a contraindication or a known suspected history of allergy, hypersensitivity or idiosyncratic reaction to trial medications
Has uncontrolled depression, anxiety, psychiatric, or neurological disorder that might interfere with trial study assessments
Has a medical condition or receiving medication such that, in the opinion of the investigator, participating in the trial would pose a health risk to the subject or might interfere with the study outcome
Has a known or suspected history of drug or alcohol abuse. A subject with a history of alcohol use disorder that has ≥10 years sobriety will be permitted
Has received/used an investigational drug, product, or device for a clinical trial within 30 days of screening. COVID-19 vaccines are permitted if the subject is not in a clinical trial for the vaccine
Has a Body Mass Index (BMI) ≥40 kg/m2
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note